Literature DB >> 14522256

Myc-driven murine prostate cancer shares molecular features with human prostate tumors.

Katharine Ellwood-Yen1, Thomas G Graeber, John Wongvipat, M Luisa Iruela-Arispe, JianFeng Zhang, Robert Matusik, George V Thomas, Charles L Sawyers.   

Abstract

Increased Myc gene copy number is observed in human prostate cancer. To define Myc's functional role, we generated transgenic mice expressing human c-Myc in the mouse prostate. All mice developed murine prostatic intraepithelial neoplasia followed by invasive adenocarcinoma. Microarray-based expression profiling identified a Myc prostate cancer expression signature, which included the putative human tumor suppressor NXK3.1. Human prostate tumor databases revealed modules of human genes that varied in concert with the Myc prostate cancer signature. This module includes the Pim-1 kinase, a gene known to cooperate with Myc in tumorigenesis, and defines a subset of human, "Myc-like" human cancers. This approach illustrates how genomic technologies can be applied to mouse cancer models to guide evaluation of human tumor databases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14522256     DOI: 10.1016/s1535-6108(03)00197-1

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  357 in total

1.  Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer.

Authors:  Guang Yang; Alexei A Goltsov; Chengzhen Ren; Shinji Kurosaka; Kohei Edamura; Richard Logothetis; Francesco J DeMayo; Patricia Troncoso; Jorge Blando; John DiGiovanni; Timothy C Thompson
Journal:  Mol Cancer Res       Date:  2011-12-05       Impact factor: 5.852

2.  A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.

Authors:  Sang Hyun Lee; George Poulogiannis; Saumyadipta Pyne; Shidong Jia; Lihua Zou; Sabina Signoretti; Massimo Loda; Lewis Clayton Cantley; Thomas M Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

3.  Progression of prostate carcinogenesis and dietary methyl donors: temporal dependence.

Authors:  Shabana Shabbeer; Simon A Williams; Brian W Simons; James G Herman; Michael A Carducci
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-02

4.  Regulation of Skp2 levels by the Pim-1 protein kinase.

Authors:  Bo Cen; Sandeep Mahajan; Marina Zemskova; Zanna Beharry; Ying-Wei Lin; Scott D Cramer; Michael B Lilly; Andrew S Kraft
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

5.  Interleukin-17 promotes metastasis in an immunocompetent orthotopic mouse model of prostate cancer.

Authors:  David Cunningham; Qiuyang Zhang; Sen Liu; Keshab R Parajuli; Qiang Nie; Lin Ma; Allen Zhang; Zhenbang Chen; Zongbing You
Journal:  Am J Clin Exp Urol       Date:  2018-06-15

Review 6.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  GGAP2/PIKE-a directly activates both the Akt and nuclear factor-kappaB pathways and promotes prostate cancer progression.

Authors:  Yi Cai; Jianghua Wang; Rile Li; Gustavo Ayala; Michael Ittmann; Mingyao Liu
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

8.  RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition.

Authors:  Riet van der Meer; Ha Yong Song; Seong-Hoon Park; Sarki A Abdulkadir; Meejeon Roh
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

9.  Development of a stress response therapy targeting aggressive prostate cancer.

Authors:  Hao G Nguyen; Crystal S Conn; Yae Kye; Lingru Xue; Craig M Forester; Janet E Cowan; Andrew C Hsieh; John T Cunningham; Charles Truillet; Feven Tameire; Michael J Evans; Christopher P Evans; Joy C Yang; Byron Hann; Constantinos Koumenis; Peter Walter; Peter R Carroll; Davide Ruggero
Journal:  Sci Transl Med       Date:  2018-05-02       Impact factor: 17.956

10.  The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer.

Authors:  Hui Shen; Nathan Powers; Nitin Saini; Clay E S Comstock; Ankur Sharma; Katherine Weaver; Monica P Revelo; William Gerald; Erin Williams; Walter J Jessen; Bruce J Aronow; Gary Rosson; Bernard Weissman; Christian Muchardt; Moshe Yaniv; Karen E Knudsen
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.